Shilan Motamed Vaziri
About Shilan Motamed Vaziri
Shilan Motamed Vaziri is the Senior Director and Viral Vector Clinical Manufacturing Lead at Bristol Myers Squibb in Summit, New Jersey, with extensive experience in biopharmaceutical manufacturing and technology transfer.
Company
Shilan Motamed Vaziri currently holds the position of Senior Director - Viral Vector Clinical Manufacturing Lead at Bristol Myers Squibb. Operating out of Summit, New Jersey, she plays a key role in the company's viral vector clinical manufacturing processes.
Title
As the Senior Director - Viral Vector Clinical Manufacturing Lead at Bristol Myers Squibb, Shilan Motamed Vaziri oversees critical aspects of viral vector clinical manufacturing. Her role focuses on ensuring the efficacy and regulatory compliance of these advanced biological products.
Education and Expertise
Shilan Motamed Vaziri earned her Ph.D. in Chemical Engineering from the New Jersey Institute of Technology, where she also worked as a researcher and teaching assistant for five years. She also holds a B.Sc. in Chemical Engineering - Polymer Industries from Isfahan University of Technology. Her academic background is complemented by extensive experience in technology transfers, validations, and aseptic drug product manufacturing.
Professional Background
Shilan Motamed Vaziri has built a robust career at Bristol Myers Squibb, progressing through various roles. She has served as Director - New Product and Lifecycle Technology, Associate Director - Manufacturing Science and Technology (Biologics Drug Product), and Principal Engineer among other positions. Her career journey includes experience in quality compliance, supply chain management, and leading cross-functional groups in the biopharmaceutical sector.
Biopharmaceutical Experience
Shilan Motamed Vaziri participated in the Accelerated Leadership Rotational Program at Bristol Myers Squibb, which broadened her range of bio-pharma experience. Shilan is known for her expertise in aseptic drug product manufacturing, technology transfers, and commercial manufacturing of sterile products and biologics drug substances. She has a proven track record in managing complex changes and high-performing teams within the fast-paced biopharmaceutical industry.